Recent insider trends for Flexion Therapeutics, Inc. (NASDAQ:FLXN) have caught the attention of investors. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock. In the case of FLXN, the data has some interesting implications for where the stock might be headed.
Institutions own 83.00% of Flexion Therapeutics, Inc. (FLXN)’s shares. The total value of these holdings, in millions, is $692. Among active positions in the latest quarter, 64 holders increased their positions by a total of 4.25 million shares, 43 holders decreased the positions by a total of 1.79 million shares, and 14 holders held their positions. This works out to a net increase in ownership of 2.46 million shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 20 holders initiated new positions by a total of 1.56 million shares and 19 holders exited their positions by a total of 1.13 million shares. This nets out to an increase of 426472 shares and is a bullish sign for FLXN.
In the last three months, insiders executed a total of 3 trades. 3 of these were buys. Insider ownership increased by a total of 5375 shares, which suggests that FLXN’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 14 buys and 8 sells, and ownership decreased by a net of 5453 shares.
Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Flexion Therapeutics, Inc. (NASDAQ:FLXN)’s short interest is 6.47 million shares, or 26.59% of the float. This represents a decrease of -3% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for FLXN. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that FLXN is a Strong buy, which implies that FLXN is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Flexion Therapeutics, Inc. (NASDAQ:FLXN) is undervalued.